Fate Therapeutics, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of Class I Directors: Karin Jooss, Ph.D.

Fate Therapeutics, Inc.’s own tally for this item (“Elect Director: Karin Jooss, Ph.D.”): 59,655,584 for, 1,395,078 withheld, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 18,800,389 for, 119,786 withheld, 5 abstained.

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

Description as filed by funds: Election of Class I Directors: Laura J. Hamill

Fate Therapeutics, Inc.’s own tally for this item (“Elect Director: Laura J. Hamill”): 60,850,004 for, 200,658 withheld, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 18,920,180 for.

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

Description as filed by funds: Election of Class I Directors: Robert S. Epstein, M.D., M.S.

Fate Therapeutics, Inc.’s own tally for this item (“Elect Director: Robert S. Epstein, M.D., M.S.”): 59,332,820 for, 1,717,842 withheld, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 18,558,811 for, 361,365 withheld, 4 abstained.

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

Description as filed by funds: TO APPROVE A PROPOSAL TO AMEND AND RESTATE THE COMPANY'S 2022 STOCK OPTION AND INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE THEREUNDER.

Fate Therapeutics, Inc.’s own tally for this item (“(iv) Approval of an amendment and restatement of the 2022 A&R Plan to increase the number of shares of Common Stock reserved for issuance thereunder.”): 46,645,607 for, 14,304,810 against, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 17,025,443 for, 1,894,736 against.

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.

Fate Therapeutics, Inc.’s own tally for this item (“(iii) Non-binding advisory vote on the compensation of the Company's named executive officers.”): 59,168,689 for, 1,808,669 against, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 43 managers: 18,673,312 for, 246,867 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 111 managers: 34,160,338 for, 772,933 against, 4,500 abstained, 128,000 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO APPROVE THE RATIFICATION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.

Fate Therapeutics, Inc.’s own tally for this item (“(ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 86,552,927 for, 308,582 against, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 18,920,180 for.

Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.